Gilead Sciences Target price 2024 - Analyst rating & recommendation
Gilead Sciences Classifications & Recommendation:
Gilead Sciences Target price
| Target price | $82.45 |
| Course | $68.64 |
| Price potential | 20.12% |
| Number of estimates | 25 |
| 25 Analysts have issued a price target Gilead Sciences 2025 . The average Gilead Sciences target price is $82.45. This is 20.12% higher than the current share price. The highest price target is $119.00 73.37% , the lowest is $67.00 2.39% . | |
| A rating was issued by 32 analysts: 15 Analysts recommend Gilead Sciences to buy, 17 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst estimates: Analysts believe that the Gilead Sciences share has an average upside potential 2025 of 20.12% . Most analysts recommend the Gilead Sciences share at Hold. |
Sales and margin forecast 2024, 2025 to 2028
27 Analysts have issued a sales forecast Gilead Sciences 2024 . The average Gilead Sciences sales estimate is $27.6b . This is 0.61% higher than the turnover of the last 12 months(TTM). The highest sales forecast is $28.1b 2.34% , the lowest is $27.0b 1.46% .
This results in the following potential growth figures:
Sales forecast
| 2023 | $27.1b | 0.10% |
|---|---|---|
| 2024 | $27.6b | 1.95% |
| 2025 | $28.0b | 1.53% |
| 2026 | $28.8b | 2.94% |
| 2027 | $29.8b | 3.32% |
| 2028 | $31.1b | 4.24% |
13 Analysts have issued an Gilead Sciences EBITDA forecast 2024. The average Gilead Sciences EBITDA estimate is $9.0b . This is 25.20% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $10.3b 14.40% , the lowest is $7.4b 38.82% .
This results in the following potential growth figures and future EBITDA margins:
EBITDA forecast
| 2023 | $12.4b | 3.29% |
|---|---|---|
| 2024 | $9.0b | 27.38% |
| 2025 | $13.4b | 48.18% |
| 2026 | $13.6b | 1.82% |
| 2027 | $14.4b | 6.01% |
| 2028 | $15.1b | 4.68% |
EBITDA margin
| 2023 | 45.96% | 3.19% |
|---|---|---|
| 2024 | 32.74% | 28.77% |
| 2025 | 47.78% | 45.94% |
| 2026 | 47.26% | 1.09% |
| 2027 | 48.50% | 2.62% |
| 2028 | 48.70% | 0.41% |
16 Gilead Sciences Analysts have issued a net profit forecast 2024. The average Gilead Sciences net profit estimate is $442m . This is 1.45% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $872m 94.44% , the lowest is $137m 69.44% .
This results in the following potential growth figures and future net margins:
Net profit forecast
| 2023 | $5.6b | 23.63% |
|---|---|---|
| 2024 | $442m | 92.12% |
| 2025 | $6.7b | 1,405.94% |
| 2026 | $7.2b | 8.38% |
| 2027 | $7.5b | 4.63% |
| 2028 | $8.3b | 9.88% |
Net margin
| 2023 | 20.72% | 23.75% |
|---|---|---|
| 2024 | 1.60% | 92.28% |
| 2025 | 23.77% | 1,385.63% |
| 2026 | 25.02% | 5.26% |
| 2027 | 25.34% | 1.28% |
| 2028 | 26.71% | 5.41% |
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028
16 Analysts have issued a Gilead Sciences forecast for earnings per share. The average Gilead Sciences <a href=/blog/eps>EPS is $0.35 . This is 2.78% lower than earnings per share in the financial year 2023. The highest <a href=/blog/eps>EPS forecast is $0.70 94.44% , the lowest is $0.11 69.44% .
This results in the following potential growth figures and future valuations:
Earnings per share
| 2023 | $4.50 | 23.63% |
|---|---|---|
| 2024 | $0.35 | 92.22% |
| 2025 | $5.34 | 1,425.71% |
| 2026 | $5.79 | 8.43% |
| 2027 | $6.06 | 4.66% |
| 2028 | $6.66 | 9.90% |
P/E ratio
| Current | 191.36 | 1,001.67% |
|---|---|---|
| 2024 | 193.48 | 1.11% |
| 2025 | 12.85 | 93.36% |
| 2026 | 11.85 | 7.78% |
| 2027 | 11.33 | 4.39% |
| 2028 | 10.31 | 9.00% |
Based on analysts' sales estimates for 2024, the Gilead Sciences share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of 3.79 and an <a href=/blog/kurs-umsatz-verhaeltnis-kuv-einfach-erklaert>P/S ratio of 3.10 .
This results in the following potential growth figures and future valuations:
EV/Sales
| Current | 3.81 | 11.19% |
|---|---|---|
| 2024 | 3.79 | 0.51% |
| 2025 | 3.73 | 1.51% |
| 2026 | 3.63 | 2.86% |
| 2027 | 3.51 | 3.21% |
| 2028 | 3.37 | 4.07% |
P/S ratio
| Current | 3.12 | 12.90% |
|---|---|---|
| 2024 | 3.10 | 0.61% |
| 2025 | 3.05 | 1.51% |
| 2026 | 2.97 | 2.86% |
| 2027 | 2.87 | 3.21% |
| 2028 | 2.75 | 4.07% |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
